Antibody Fc: book cover

Antibody Fc:

Linking Adaptive and Innate Immunity

Edited by
  • Margaret Ackerman, Dartmouth College, Hanover, NH, USA

This is the first comprehensive text to synthesize the literature, describing these functions and presenting the variety of human genetic, mouse model, in vitro and providing clinical evidence of the importance and the dramatic variability of antibodies to influence the immune response. Antibodies represent the correlate of protection for numerous vaccines, and are the most rapidly growing class of drugs, representing a tremendous economic and therapeutic sector ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells, as well as providing a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells. Despite it’s nomenclature, a number of factors influence the ability of the constant domain to recruit effector mechanisms. There is a vast literature regarding antibody effector function, indicating that it is a high impact and dynamic area.

Audience
vaccinologists, immunologists, microbiologists, oncologists, protein engineers, in academic and industrial research institutions; graduate students in immunology and vaccinology.

Hardbound, 450 Pages

Published: October 2013

Imprint: Academic Press

ISBN: 978-0-12-394802-1

Contents

  • Part 1:  Effector Mechanisms
    Ch 1: ADCC: Antibody dependent cellular cytotoxicity
    Ch 2:. ADCP: Antibody dependent cellular phagocytosis
    Ch 3: ADCDC: Antibody dependent complement dependent cytotoxicity
    Ch 4: Trapping in mucus

    Part 2: Effector Cells
    Ch 5: NK cells
    Ch 6: Phagocytes
    Ch 7: B cells

    Part 3: FcR
    Ch 8: Activating Receptors FcgR1, FcgR2a, FcgR3a
    Ch 9: Inhibitory receptor FcgR2b
    Ch 10: Comparison of human, mouse, and primate FcgR

    Part 4: Variability of the Fc Domain
    Ch 11: Antibody Subclasses
    Ch 12: Antibody Glycosylation

    Part 5: Genetic Associations
    Ch 13: Autoimmunity
    Ch 14: Infectious disease
    Ch 15: Monoclonal Antibody Therapy

    Part 6: Evolving areas
    Ch 16: Competition between mechanisms
    Ch 17: Fc driven immunotherapy
    Ch 18: FcR as therapeutic targets
    Ch 19: Engineered Fc domains
    Ch 20: Tolerizing vs activating pathways
    Ch 21: Defense/evasion mechanisms against Fc activity
    Ch 22: Pathogenic exploitation of Fc activity

Advertisement

advert image